A Clinical Evaluation of a Hepatitis C Nosode in the Treatment of Hepatitis C.

Abstract

Upon identifying the need for an alternative treatment option in the management of hepatitis C to decrease viral load and improve health parameters, the investigator has developed the hepatitis C virus (HCV) nosode. An open-label observational study in 24 HCV-positive individuals was conducted by using the HCV nosode at 30C and 50C potencies. In this clinical trial, the HCV nosode was administered to HCV-positive participants. From week 12 to week 24, the mean viral load decreased; the median viral load decreased by half, from 1,557,567.50 IU/mL to 789,265.50 IU/mL. However, at 24 weeks, the average viral load increased significantly (p = 0.2206) in the participants completing the trial. The study has shown a double population: a large set of responders with marked improvement (week 12 [p = 0.0120] and week 24 [p = 0.0304] and from week 12 to week 24 [p = 0.0028]) and a small set of nonresponders with increasing viral load (week 12 [p = 0.0120] and week 24 [p = 0.0304] and from week 12 to week 24 [p = 0.0028]). Most participants in this study showed improvement in appetite and weight gain. The treatment using the nosode was found to be safe in the tested population. The HCV viral load was affected by using ultra-diluted preparation sourced from HCV, as per the Law of Similars, in responders. Further studies of longer duration in patients with uniform baseline characteristics and those that adjust the potency to the individual participant's requirement are recommended.